Indian Journal of Urology (Jan 2022)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?

  • Abhay Singh Gaur

DOI
https://doi.org/10.4103/iju.iju_229_22
Journal volume & issue
Vol. 38, no. 4
pp. 319 – 320

Abstract

Read online

No abstracts available.